Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -10.89% is 50% above its 3-year average of -21.78%, around the middle of its 3-year range (-63.01%–16.38%).
73.91% above its 12-month average of -41.74%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-03-31): -63.01%.
NET PROFIT MARGIN
-10.89%
NET PROFIT MARGIN AVG TTM
-41.74%
NET PROFIT MARGIN AVG 3Y
-28.14%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+73.91%
CURRENT VS 3Y AVG
+61.31%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-4088.46%
vs the sector median at left
WORK Medical Technology Group Ltd. Class A
Market Cap
$3.63M
Net Profit Margin
-10.89%
TTM Avg
-41.74%
3Y Avg
-28.14%
5Y Avg
N/A
Market Cap
$3.65M
Net Profit Margin
0.00%
TTM Avg
-3826.38%
3Y Avg
-9879.36%
5Y Avg
-6586.24%
Market Cap
$3.65M
Net Profit Margin
-694.19%
TTM Avg
-257.90%
3Y Avg
-726.73%
5Y Avg
-1357.15%
Market Cap
$3.53M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.50M
Net Profit Margin
-105.71%
TTM Avg
-81.70%
3Y Avg
-1471.40%
5Y Avg
-1177.12%
Market Cap
$3.90M
Net Profit Margin
-730.23%
TTM Avg
-1020.41%
3Y Avg
-1573.84%
5Y Avg
-1133.48%
Market Cap
$3.93M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
64.44%
5Y Avg
-64.28%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| WORK Medical Technology Group Ltd. Class A (WOK) | $3.63M | -10.89% | -41.74% | -28.14% | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | 0.00% | -3826.38% | -9879.36% | -6586.24% |
| Evogene Ltd. (EVGN)vs › | $3.65M | -694.19% | -257.90% | -726.73% | -1357.15% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moolec Science S.A. (MLEC)vs › | $3.50M | -105.71% | -81.70% | -1471.40% | -1177.12% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | -730.23% | -1020.41% | -1573.84% | -1133.48% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | 0.00% | 0.00% | 64.44% | -64.28% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | -4139.38% | -3617.24% | -2890.13% | -2863.43% |
Operating Margin
-25.3%
Net Profit Margin
-10.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | -63.01% |
| 2025-09-30 | -20.47% |
| 2025-03-29 | 0.29% |
| 2024-09-29 | -60.01% |
| 2024-03-29 | 4.27% |
| 2023-09-29 | -29.94% |
| 2023-03-29 | 16.38% |